NEW YORK STATE ASSEMBLY MEMORANDUM IN SUPPORT OF LEGISLATION submitted in accordance with Assembly Rule III, Sec 1(f)
BILL NUMBER: A6506A
TITLE OF BILL:
An act to amend the general business law, in relation to prohibiting the
sale of xylazine
PURPOSE OR GENERAL IDEA OF BILL:
To prohibit the sale of xylazine without proof of its intended use for
Institutional, veterinary, or scientific purposes.
SUMMARY OF PROVISIONS:
Section 1 prohibits the sale and delivery of xylazine in the State with-
out-proof of its intended use for institutional, veterinary or scientif-
Section 2 sets the effective date.
We are facing an opioid epidemic of historic levels in the State of New
York. Outcomes for individuals are worsening as additives such as fenta-
nyl and xylazine are being added to the formula. Unlike fentanyl, the
effects of which can be reversed with opioid antagonists like naloxone,.
xylazine is a tranquilizer with no equivalent reversal agent. Further-
more, xylazine can cause not only death but many other complications
including unconsciousness and open sores.
We need to be proactive and prevent xylazine from being added to opioids
being sold on the street to avoid the devastating effects we have seen
in other parts of the country. This bill would prohibit the sale of
xylazine in person or online without proof that the buyer is using it
for its intended use, thus adding some control over the sale and ship-
ment of xylazine in our state.
PRIOR LEGISLATIVE HISTORY:
This act shall take effect immediately.
STATE OF NEW YORK
2023-2024 Regular Sessions
April 12, 2023
Introduced by M. of A. TAPIA, ZACCARO, ALVAREZ, LAVINE, RAJKUMAR,
DE LOS SANTOS, SIMONE, REYES, SOLAGES, DICKENS, RIVERA, RAMOS, ARDILA,
BUTTENSCHON, FORREST, SHIMSKY, LUCAS, CUNNINGHAM, CRUZ, SIMON, SAYEGH,
EPSTEIN, BICHOTTE HERMELYN, BORES -- read once and referred to the
Committee on Consumer Affairs and Protection -- reported and referred
to the Committee on Codes -- committee discharged, bill amended,
ordered reprinted as amended and recommitted to said committee
AN ACT to amend the general business law, in relation to prohibiting the
sale of xylazine
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. The general business law is amended by adding a new section
2 392-k to read as follows:
3 § 392-k. Sale of xylazine. 1. For purposes of this section, the term
4 "xylazine" shall mean a pharmaceutical drug used for sedation, anes-
5 thesia, muscle relaxation, and analgesia in animals such as horses,
6 cattle, and other non-human mammals.
7 2. No person, corporation, partnership, limited liability company,
8 firm, online platform, or any other business entity doing business with-
9 in this state shall sell, offer for sale, or deliver xylazine to indi-
10 viduals without proof of its intended use for institutional, veterinary,
11 or scientific purposes.
12 3. No person, corporation, partnership, limited liability company,
13 firm, online platform, or other business entity doing business within
14 this state shall sell, offer for sale, or deliver xylazine to individ-
15 uals under the age of twenty-one.
16 4. Any person, corporation, partnership, limited liability company,
17 firm, online platform or other business entity doing business within
18 this state which sells, offers for sale, or distributes xylazine, shall
19 require and retain sales records, proof of age, and proof of use from
20 all purchasers.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 is old law to be omitted.
A. 6506--A 2
1 5. Any person, corporation, partnership, limited liability company,
2 firm, online platform, or other business entity doing business within
3 this state that violates the provisions of this section by selling,
4 offering for sale, or delivery of xylazine shall be subject to a civil
5 penalty of not more than five hundred dollars per violation, recoverable
6 in an action by the attorney general of the state of New York.
7 § 2. This act shall take effect immediately.